Moderna (MRNA) on Tuesday announced that it has kicked off a Phase 1 clinical trial of its experimental vaccine targeting the Bundibugyo strain of Ebola virus, ahead of a closely watched regulatory decision on its influenza vaccine expected this week.MRNA shares were up 4.4% at the time of writing…
The U.S. Food and Drug Administration is set to rule on five closely watched treatments in August from Moderna, Lantheus Holdings, Bristol Myers Squibb, Capricor Therapeutics and Ultragenyx Pharmaceutical.Decisions are due by August 23 at the latest on therapies ranging from an mRNA flu vaccine to…
Q2 2026 revenue exceeded guidance at $145 million, with improved cost discipline and a net loss of $782 million. Pipeline advanced with key regulatory milestones in flu and RSV vaccines, and oncology programs showed durable benefit. Revenue growth of up to 10% is expected for 2026.Based on Moderna…
Biotechnology company Moderna NASDAQ:MRNAwill be announcing earnings results this Friday before market hours. Here’s what investors should know.Moderna beat analysts’ revenue expectations last quarter, reporting revenues of $389 million, up 260% year on year. It was an incredible quarter for the co…
Moderna, Inc. (NASDAQ:MRNA) has begun paying into a March 2026 up-to-$2.25B LNP patent settlement—$178M on July 8 covering Arbutus’s share and litigation costs—while facing a separate patent suit from Sanofi over Translate Bio mRNA/LNP tech tied to COVID-19 vaccines.Previous Week Recap…
CAMBRIDGE, MA / ACCESS Newswire / July 9, 2026 / Moderna, Inc. NASDAQ:MRNA, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, July 31, 2026 to report its second quarter 2026 financial results, and provide a corporate update.A live webcast of the call wi…
Shares of Arbutus Biopharma (ABUS) jumped 6% on Tuesday as investors awaited a payout from vaccine developer Moderna (MRNA) under a litigation settlement.Settlement Payment Expected This WeekIn March, Arbutus and its partner Genevant Sciences, a unit of Roivant Sciences (ROIV), reached a global set…
(14:33 GMT) Moderna Price Target Raised to $38.00/Share From $34.00 by B of A Securities
Shares of Moderna MRNA have surged 33.5% over the past week, adding nearly $8 billion to the company's market value.The rally was sparked by Moderna's Science Day, where management outlined its vision to evolve beyond vaccines into a diversified biotechnology company. The event showcased how the co…
